TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11092071

Group type: EXPERIMENTAL
Intervention: Enhanced services program providing transportation, outreach, and child-care services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of access services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular substance abuse treatment programs
Number of subjects: 0
Study: 9497918

Group type: EXPERIMENTAL
Intervention: One step reverse transcriptase polymerase chain reaction (RT‐PCR) protocol for BCR‐ABL chimaera detection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Published RT‐PCR procedures
Number of subjects: 50
Study: 8097170

Group type: EXPERIMENTAL
Intervention: Broxaterol (200 micrograms)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study: 3102303

Group type: EXPERIMENTAL
Intervention: Intensive nasogastric tube-feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best oral feeding
Number of subjects: 0
Study: 29653635

Group type: EXPERIMENTAL
Intervention: 100 mg daily aspirin
Number of subjects: 15480

Group type: EXPERIMENTAL
Intervention: 1 g omega-3 FA daily
Number of subjects: 15480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15480
Study: 28281457

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 25061233

Group type: EXPERIMENTAL
Intervention: Dried blood spot testing (DBST) for HCV testing with training and logistic support
Number of subjects: 6
Study: 23717490

Group type: EXPERIMENTAL
Intervention: BMS-936558 (0.1 mg/kg or 10 mg/kg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: BMS-936558 (10 mg/kg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: BMS-936558
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 21389841

Group type: EXPERIMENTAL
Intervention: Aerobic high-intensity hybrid exercise training (3 times a week for 8 weeks)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aerobic high-intensity hybrid exercise training
Number of subjects: 6
Study: 18641581

Group type: EXPERIMENTAL
Intervention: WFG‐LASIK
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: WFG‐PRK
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: WFG‐LASIK and WFG‐PRK
Number of subjects: 61
Study: 16557409

Group type: EXPERIMENTAL
Intervention: Tele-visit system used for 6 weeks after discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 14636798

Group type: EXPERIMENTAL
Intervention: CD-ROM
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Internet
Number of subjects: 188

Group type: COMPARATOR
Intervention: Pamphlets
Number of subjects: 188
Study: 10817440

Group type: EXPERIMENTAL
Intervention: Laparosonic coagulating shears (LCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 40
Study: 8661976

Group type: EXPERIMENTAL
Intervention: Intranasal synthetic SCT (200 IU daily)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: COMPARATOR
Intervention: Thrice-weekly calcitonin
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Proximal femur (all groups)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Biochemical markers (all groups)
Number of subjects: 117
Study: 1804669

Group type: EXPERIMENTAL
Intervention: Almitrine (100 mg.day-1, intermittent schedule)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 27
Study: 6289963

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 62.5 mg
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 32.5 mg
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (all doses)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Kanamycin 2 g
Number of subjects: 188
Study: 31824142

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Stretch exercise
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Changes in serum BDNF
Number of subjects: 17
Study: 29037658

Group type: EXPERIMENTAL
Intervention: Artificial device training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard device training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Artificial device training combined with elastic band exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard device training combined with elastic band exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Artificial device (with or without EB exercise)
Number of subjects: 40
Study: 25855073

Group type: EXPERIMENTAL
Intervention: Postoperative drug therapy to prevent disease recurrence
Number of subjects: 174
Study: 23980084

Group type: EXPERIMENTAL
Intervention: Brivanib 800 mg once daily orally
Number of subjects: 1155

Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice daily orally
Number of subjects: 1155
Study: 21725579

Group type: EXPERIMENTAL
Intervention: Wilate (high purity, human plasma-derived VWF/FVIII concentrate)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Humate-P (intermediate purity, human plasma-derived VWF/FVIII concentrate)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Wilate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Humate-P
Number of subjects: 22
Study: 19850525

Group type: EXPERIMENTAL
Intervention: Alteplase (0.9 mg/kg bodyweight)
Number of subjects: 821
Study: 16362400

Group type: EXPERIMENTAL
Intervention: 15-min brisk semi-self-paced walk
Number of subjects: 60

Group type: COMPARATOR
Intervention: Passive control condition
Number of subjects: 60
Study: 15296367

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (3 MHz, 0.5 W/cm2, for 10 minutes)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (3 MHz, 1.0 W/cm2, 50% duty cycle, for 10 minutes)
Number of subjects: 16
Study: 11055474

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil/hydrochlorothiazide (candesartan/HCT; 16/12.5 mg)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Losartan/hydrochlorothiazide (losartan/HCT; 50/12.5 mg)
Number of subjects: 299
Study: 8379551

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program (10 weeks of group therapy)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Slow taper condition alone
Number of subjects: 33
Study: 2875594

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl 0.1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl 0.1 mg-droperidol 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31581295

Group type: EXPERIMENTAL
Intervention: 100% estimated caloric needs (ECN)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 40% estimated caloric needs (ECN)
Number of subjects: 35
Study: 29665102

Group type: EXPERIMENTAL
Intervention: 5 days of broad-spectrum antibiotics followed by FMT from a donor enriched in Lachnospiraceae and Ruminococcaceae
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC, no antibiotics/FMT)
Number of subjects: 0
Study: 26763986

Group type: EXPERIMENTAL
Intervention: VEPEMB (vinblastine, cyclophosphamide, procarbazine, prednisone, etoposide, mitoxantrone, bleomycin)
Number of subjects: 54

Group type: COMPARATOR
Intervention: ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: VEPEMB
Number of subjects: 54

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 54
Study: 24446022

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation with early reablation
Number of subjects: 245
Study: 22200586

Group type: EXPERIMENTAL
Intervention: Pedometer group
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Pedometer group (among participants who completed the intervention)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 655
Study: 21052040

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study: 18274940

Group type: COMPARATOR
Intervention: Active recovery
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cold water immersion (10 degrees C, 15 degrees C, 20 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 10
Study: 16181465

Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil (5-FU) cream applied twice daily for 3 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% 5-fluorouracil (5-FU) cream applied twice daily for 1 day per week for 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison of inflammation scores
Number of subjects: 20
Study: 12680810

Group type: EXPERIMENTAL
Intervention: Treatment 2 (T2) - Communicative Reading Strategies (CRS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treatment 1 (T1) - Traditional decoding‐based feedback strategies
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 12
Study: 10686664

Group type: EXPERIMENTAL
Intervention: L-carnitine (3 x 1 g daily for 120 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8836270

Group type: EXPERIMENTAL
Intervention: Propofol (15-20 mg/kg.h) with 30% O2 in air
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol (10-15 mg/kg.h) with 30% O2 in N2O
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isoflurane (1.0-1.5 Vol%) with 30% O2 in N2O
Number of subjects: 90
Study: 1364936

Group type: EXPERIMENTAL
Intervention: Enteric-coated naproxen tablets (ECT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Plain naproxen tablets (PT)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both ECT and PT
Number of subjects: 98
Study: 4055463

Group type: EXPERIMENTAL
Intervention: Skills-building methods
Number of subjects: 331

Group type: COMPARATOR
Intervention: Discussion methods
Number of subjects: 331

Group type: COMPARATOR
Intervention: Pretest-posttest
Number of subjects: 331

Group type: COMPARATOR
Intervention: Posttest only
Number of subjects: 331
Study: 31140540

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 108
Study: 29455404

Group type: EXPERIMENTAL
Intervention: Online lecture (15-min duration, watched 1-2 weeks prior to surgery)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no online lecture)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 200
Study: 26935407

Group type: EXPERIMENTAL
Intervention: MIS-RDAVR via upper hemisternotomy (EDWARDS INTUITY)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MIS-RDAVR
Number of subjects: 100

Group type: COMPARATOR
Intervention: FS-AVR
Number of subjects: 100
Study: 24107324

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/day
Number of subjects: 2340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2340
Study: 22954919

Group type: EXPERIMENTAL
Intervention: Multi-frequency low-dose intravenous iron (iron sucrose 25 mg, twice a week for 8 weeks)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Less-frequency regular-dose intravenous iron (iron sucrose 100 mg, once every two weeks for 8 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Non-iron group
Number of subjects: 58
Study: 20488261

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (15mg RE)
Number of subjects: 888

Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 888
Study: 18560640

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Sodium fluoride gel
Number of subjects: 149

Group type: COMPARATOR
Intervention: Dental health education program
Number of subjects: 149
Study: 16012211

Group type: EXPERIMENTAL
Intervention: Single Bond (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adper Prompt (Group 2)
Number of subjects: 20
Study: 12401757

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg b.i.d.
Number of subjects: 203

Group type: COMPARATOR
Intervention: Glyburide (GLB) titrated to mean 10.5 mg/day for the first 8 weeks
Number of subjects: 203
Study: 10350385

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g every 12 h for a minimum of 3 days and up to 14 days
Number of subjects: 151

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g every 12 h for a minimum of 3 days and up to 14 days
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 151

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 151
Study: 9166486

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU/kg three times a week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional supportive treatment alone
Number of subjects: 30
Study: 1613829

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day rhGH
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6089540

Group type: EXPERIMENTAL
Intervention: lacto-ovo vegetarian diet
Number of subjects: 36
Study: 31351998

Group type: EXPERIMENTAL
Intervention: Acupressure at Zusanli (ST‐36), Hegu (LI‐4), and Sanyingjiao (SP‐6)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham pressure (placebo group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 90
Study: 29641522

Group type: EXPERIMENTAL
Intervention: Pre-surgical psychological assessment using STAI (State-Trait Anxiety Inventory) and HADS-A (Hospital Anxiety and Depression Scale - Anxiety)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Pre-surgical psychological assessment using MFI (Multidimensional Fatigue Inventory)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Pre-surgical psychological assessment using HADS-D (Hospital Anxiety and Depression Scale - Depression)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Pre-surgical psychological assessment using STAS (State-Trait Anger Scale)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Pre-surgical psychological assessment including self-efficacy and sex
Number of subjects: 398
Study: 27893130

Group type: EXPERIMENTAL
Intervention: Inpatient palliative care (n=81), seen by palliative care clinicians at least twice a week during HCT hospitalization.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Inpatient palliative care (n=81)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Caregivers of patients in the intervention group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard transplant care (n=79)
Number of subjects: 160
Study: 24354738

Group type: EXPERIMENTAL
Intervention: 5% sodium bicarbonate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 60
Study: 23006657

Group type: EXPERIMENTAL
Intervention: Dedicated clinic (n=1336)
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: Fasting (n=668)
Number of subjects: 2340

Group type: COMPARATOR
Intervention: Parramatta pathology centre without a reminder (n=334)
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: Parramatta pathology centre with a reminder (n=336)
Number of subjects: 2340

Group type: COMPARATOR
Intervention: Pathology centres (n=1004)
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 2340

Group type: COMPARATOR
Intervention: Comparison of dedicated clinics vs pathology centres
Number of subjects: 2340
Study: 20208067

Group type: EXPERIMENTAL
Intervention: Patient self-report of cardiovascular diagnoses
Number of subjects: 7640

Group type: EXPERIMENTAL
Intervention: Individual characteristics (e.g., choice of general practitioner, male gender, age)
Number of subjects: 7640
Study: 17389624

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.67 +/- 0.14 mg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH, bolus of 1500 IU followed by infusion of 2750 IU)
Number of subjects: 22
Study: 15549327

Group type: EXPERIMENTAL
Intervention: 5-FU 450 mg/m2 and leucovorin 100 mg/m2 x 5 days every 4 weeks; six cycles (arm A)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 24-h infusion of high-dose 5-FU/leucovorin 2,600 mg/m2 and 500 mg/m2, two cycles of six applications (arm B)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 24-h infusion of high-dose 5-FU 2,600 mg/m2, two cycles of six applications (arm C)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 145
Study: 12377751

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 9928771

Group type: EXPERIMENTAL
Intervention: Analgesic treatment (non-opioid or opioid analgesics, antidepressants, anticonvulsants, corticosteroids)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Palliative antineoplastic treatment
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Nerve blocks
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation
Number of subjects: 593
Study: 7752902

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (PUFA) ethyl esters
Number of subjects: 20

Group type: COMPARATOR
Intervention: olive oil (as placebo)
Number of subjects: 20
Study: 2211170

Group type: EXPERIMENTAL
Intervention: Postoperative rewarming period
Number of subjects: 36
Study: 7011228

Group type: EXPERIMENTAL
Intervention: Tined endocardial electrodes
Number of subjects: 34

Group type: COMPARATOR
Intervention: Flange-tipped leads
Number of subjects: 34
Study: 30816266

Group type: EXPERIMENTAL
Intervention: In vitro transcription of the DNA pool with RNA polymerase of interest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T7 promoter variants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promoter of cyanophage Syn5 RNA polymerase
Number of subjects: 0
Study: 28601567

Group type: EXPERIMENTAL
Intervention: All evidence-based measures (prophylactic antibiotics within 60 minutes of cesarean delivery, chlorhexidine-alcohol for skin antisepsis, closure of subcutaneous layer if ≥2 cm, subcuticular skin closure with suture)
Number of subjects: 1082

Group type: COMPARATOR
Intervention: No evidence-based measures
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: All evidence-based measures
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Unscheduled cesarean delivery among those who received all evidence-based measures
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Scheduled cesarean delivery among those who received all evidence-based measures
Number of subjects: 1082
Study: 26974889

Group type: EXPERIMENTAL
Intervention: MCV4 + Tdap + bivalent rLP2086
Number of subjects: 2648

Group type: COMPARATOR
Intervention: bivalent rLP2086 alone
Number of subjects: 2648
Study: 25197015

Group type: EXPERIMENTAL
Intervention: Guided surgery
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional implant placement
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study: 22458821

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined training (CBT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No training (NT)
Number of subjects: 43
Study: 21169160

Group type: EXPERIMENTAL
Intervention: Online community arm
Number of subjects: 324

Group type: COMPARATOR
Intervention: No online community arm
Number of subjects: 324
Study: 17937565

Group type: EXPERIMENTAL
Intervention: Dietary soy supplements (part of a randomized, placebo-controlled trial)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo (control group in the trial)
Number of subjects: 216
Study: 15743397

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (200 mg over a 3 h period)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intra-arterial hydrocortisone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 11990732

Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND) 200 mg/week, intramuscularly for 8 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Various AASs at supratherapeutic dosages
Number of subjects: 34
Study: 9655532

Group type: EXPERIMENTAL
Intervention: Azithromycin (oral, for 5 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (oral, for 5 days)
Number of subjects: 29
Study: 7653817

Group type: COMPARATOR
Intervention: 3‐in‐1 block with 40 mL of 1.5% lidocaine plus epinephrine (n = 13)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 3‐in‐1 block with 50 mL of 1.5% lidocaine plus epinephrine (n = 11)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Direct obturator nerve block with 10 mL of 2% lidocaine plus epinephrine (n = 20)
Number of subjects: 44
Study: 2683439

Group type: EXPERIMENTAL
Intervention: Continuous application of 0.1% fluprednidene-21-acetate twice a day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intermittent therapy with 1 day intermission (15 patients)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intermittent therapy with 2 days intermission (16 patients)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intermittent therapy with 3 days intermission (13 patients)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fluprednidene treatment in eczema patients
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clobetasol-17-propionate
Number of subjects: 44
Study: 335225

Group type: EXPERIMENTAL
Intervention: Combined calcium and vitamin D‐2 phosphate treatment
Number of subjects: 135

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Calcium and phosphate treatment
Number of subjects: 135
Study: 31977576

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 23964

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 23964

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 23964